Tenet selling more hospitals amid discussion of company break-up

Tenet Healthcare announced it will sell eight hospitals in the U.S. and its nine hospitals and clinics in the United Kingdom, yielding up to $1 billion for the company, though breaking up the company’s three main business lines is also a possibility, according to outgoing CEO Trevor Fetter.

Presenting at the Baird 2017 Global Healthcare Conference on Sept. 6, Fetter said its U.S. divesture will involve four markets and will include the previously announced $170 million deal to sell its two Philadelphia hospitals to Paladin Healthcare. The names of the other markets and hospitals weren’t disclosed, though Fetter did say all of them are operating on thin margins of 4 percent or less.

That kind of financial performance has caused plenty of upheaval within Tenet in recent weeks. After posting an operating loss of $56 million in the second quarter, two representatives of its biggest shareholder, Glenview Capital Management, quit the Tenet board, suggesting a proxy battle may be brewing. The move led to the announcement Fetter would be leaving his roles as CEO and chairman by March 2018. Tenet also announces a “shareholder rights plan” that would allow other shareholders to buy shares at a 50 percent discount if any investor acquired 4.9 percent or more of the company.

Among the options for turning the company around is breaking it up around its main business lines: hospitals, ambulatory surgical centers and revenue cycle software. Fetter said investors are arguing both for and against such a plan, calling it "a lively debate that will and should take place” on whether operating Tenet as an integrated system is greater than the value of those lines on their own.

For now, its sticking to sales of individual hospitals. Fetter said the company hopes to announce definitive agreement on those transactions by the end of 2017.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.